Business US
Novo Nordisk Tries to Snatch a Weight-Loss Biotech From Pfizer. There Are Political Risks. – Barron’s
- Novo Nordisk Tries to Snatch a Weight-Loss Biotech From Pfizer. There Are Political Risks. Barron’s
- Novo Nordisk’s Metsera bid shows how far it’ll go to outpace competitors Axios
- Health Care Roundup: Market Talk The Wall Street Journal
- Novo makes bombshell $6.5B counteroffer to Pfizer’s obesity buy Fierce Biotech
- Novo Nordisk bids $9bn for obesity drug maker Metsera in challenge to Pfizer The Guardian
